![](https://webarchive.library.unt.edu/eot2008/20090509153758im_/http://www.cancer.gov/images/spacer.gif) |
|
![](https://webarchive.library.unt.edu/eot2008/20090509153758im_/http://www.cancer.gov/images/spacer.gif)
alvimopan A synthetic trans-3,4-dimethyl-4-(3-hydroxyphenyl) piperidine with peripherally selective opioid mu receptor antagonist activity. Alvimopan is a selective and competitive antagonist at mu-opioid receptors, found in myenteric and submucosal neurons and
the immune cells of the lamina propria in the human gut. Upon administration, this agent binds to mu-opioid receptors in the gut, thereby reversing opiod-related disturbances in gut motility. Alvimopan is approximately three to nine times more potent than naloxone. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)
![](https://webarchive.library.unt.edu/eot2008/20090509153758im_/http://www.cancer.gov/images/spacer.gif)
US brand name: | ![](https://webarchive.library.unt.edu/eot2008/20090509153758im_/http://www.cancer.gov/images/spacer.gif) | Entereg | | ![](https://webarchive.library.unt.edu/eot2008/20090509153758im_/http://www.cancer.gov/images/spacer.gif) | Code names: | ![](https://webarchive.library.unt.edu/eot2008/20090509153758im_/http://www.cancer.gov/images/spacer.gif) | ADL8-2698 LY-246376 | | ![](https://webarchive.library.unt.edu/eot2008/20090509153758im_/http://www.cancer.gov/images/spacer.gif) |
![](https://webarchive.library.unt.edu/eot2008/20090509153758im_/http://www.cancer.gov/images/spacer.gif)
![](https://webarchive.library.unt.edu/eot2008/20090509153758im_/http://www.cancer.gov/images/gray_spacer.gif)
![](https://webarchive.library.unt.edu/eot2008/20090509153758im_/http://www.cancer.gov/images/spacer.gif)
|
![](https://webarchive.library.unt.edu/eot2008/20090509153758im_/http://www.cancer.gov/images/spacer.gif) |